A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: A randomized, quadruple crossover study

Diabetes Technology and Therapeutics

Volumn 14, Issue 7, 2012, Pages 589-595

  Ma, Zhulin ^a   Parkner, Tina ^a   Frystyk, Jan ^a,b   Laursen, Torben ^b   Lauritzen, Torsten ^b   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; POSTPRANDIAL STATE; PREPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; BIPHASIC INSULINS; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN ASPART; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84863804920     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0299     Document Type: Article

References (22)

1. American Diabetes Association: Insulin administration. Diabetes Care 1998;21(Suppl 1):572-575
2. Home PD, Alberti KG: Human insulin. Clin Endocrinol Metab 1982;11:453-483
3. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes Care 1984;7:188-199
4. Ciofetta M, Lalli C, Del SP, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB: Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999;22:795-800
5. Lindholm A, Jacobsen LV: Clinical pharmacokinetics and harmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-659
6. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. A randomized doubleblind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22:801-805
7. Bretzel RG, Arnolds S, Medding J, Linn T: A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004;27:1023-1027
8. Kang S, Creagh FM, Peters JR, Brange J, Volund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 1991;14:571-577
9. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S: Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000;37:41-46
10. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21:1904-1909
11. Kaku K, Matsuda M, Urae A, Irie S: Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000;49:119-126
12. Hirsch IB, Farkas-Hirsch R, Skyler JS: Intensive insulin therapy for treatment of type I diabetes. Diabetes Care 1990; 13:1265-1283
13. Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A: Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomized multinational study. Diabetes Res Clin Pract 2001;54: 105-114
14. Devries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD: a randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med 2003;20:312-318
15. Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L: The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008;10: 479-485
16. Thorisdottir RL, Parkner T, Chen JW, Ejskjaer N, Christiansen JS: A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study. Basic Clin Pharmacol Toxicol 2009;104:216-221
17. Jacobsen LV, Sogaard B, Riis A: Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399-403
18. Raja-Khan N, Warehime SS, Gabbay RA: Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes. Vasc Health Risk Manag 2007;3:919-935
19. Mixtard 30-going, going, gone? Drug Ther Bull 2010; 48:85
20. Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH: Pre-meal insulin aspart compared with premeal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract 2006;71:131-139
21. Rys P, Pankiewicz O, Lach K, Kwaskowski A, Skrzekowska- Baran I, Malecki MT: Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab 2011;37:190-200
22. Overmann H, Heinemann L: Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-142